Document is current
Any future updates will be listed below
-
Authors
Lerch, Ondrej
Ferreira, Daniel
Stomrud, Erik
van Westen, Danielle
Tideman, Pontus
Palmqvist, Sebastian
Mattsson-Carlgren, Niklas
Hort, Jakub
Hansson, Oskar
Westman, Eric
-
Funding
Funding for this research was provided by:
Karolinska Institute
- License Information
-
More Information
Article History
Received: 5 September 2023
Accepted: 24 June 2024
First Online: 5 July 2024
Declarations
:
: The study was approved by the regional ethical committee at Lund University, Lund, Sweden. All participants gave their written informed consent to participate in the study.
: Not applicable.
: OL, DF, ES, DvW, PT, SP, NM-C, JH and EW report no competing interests. OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens.
